Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Scleroderma and Related Disorders|August 1, 2025
The serum levels of specific autoantibodies in systemic sclerosis predict a more severe skin involvementHannah Dengler, Maya Vonow-Eisenring, Mike Oliver Becker, et al.
Annals of the Rheumatic Diseases|June 8, 2018
Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR modelWanlong Wu, Suzana Jordan, Mike Oliver Becker, et al.
RMD Open|July 25, 2024
Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?Lea Stamm, Alexandru Garaiman, Mike Oliver Becker, et al.
The Journal of Rheumatology|February 1, 2024
Histogram-Based Densitometry Index to Assess the Severity of Interstitial Lung Disease in Systemic Sclerosis in Standard and Low-Dose Computed TomographyCosimo Bruni, Lorenzo Tofani, Alexandru Garaiman, et al.
Swiss Medical Weekly|April 5, 2024
Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohortKevin Windirsch, Suzana Jordan, Mike Oliver Becker, et al.
Swiss Medical Weekly|April 3, 2023
Management of giant-cell arteritis in Switzerland: an online national surveyMichele Iudici, Andrea Katharina Hemmig, Mihaela Stegert, et al.
RMD Open|November 28, 2024
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosisRucsandra Dobrota, Alexandru Garaiman, Kim Fligelstone, et al.
Rheumatology (Oxford, England)|July 29, 2022
Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC modelAlexandru Garaiman, Klaus Steigmiller, Catherine Gebhard, et al.
Rheumatology (Oxford, England)|January 8, 2025
Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohortEliane Roth, Cosimo Bruni, Liubov Petelytska, et al.
Annals of the Rheumatic Diseases|February 2, 2025
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR databaseQingran Yan, Cosimo Bruni, Alexandru Garaiman, et al.
Pageof 3